Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Key Points

The aim is to assess the effectiveness of neratinib in metastatic breast cancer with HER2 mutation and amplification.
Evaluated patients with metastatic breast cancer bearing HER2 mutation and amplification.
Administered neratinib to assess treatment response.
Patients demonstrated a positive response to neratinib treatment.
Efficacy is particularly noted in cases with both HER2 mutation and amplification.

Answers are grounded in this paper and cite their sources.

Evaluates neratinib’s impact on metastatic breast cancer in patients with HER2 mutation and amplification, suggesting treatment efficacy.

Metastatic breast cancer patients with coexistent HER2 mutation and amplification respond to neratinib.

No takes yet. Share an insight, caveat, or question.

Cocco et al. (2018) studied this question.

View Full Paper

Ask AI

Bookmark

Share